Home / Market News / $ABSI

$ABSI news and market catalysts

The 11 most recent market catalysts affecting $ABSI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

11 catalysts 3 high impact 2 bullish 3 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Neutral Impact 55
Analysts Update Price Targets and Ratings for Absci Corporation
This 8-K filing discloses that several analysts have updated their coverage on Absci Corporation. Guggenheim maintained a Buy rating but lowered its price target from $15 to $14, w…
Nov 12, 2026 Corporate Catalyst Bearish Impact 85
Absci Corporation Reports Third Quarter 2026 Financial Results
Absci Corporation's Q3 2026 earnings report shows a significant widening of its net loss to $33.3 million from $28.7 million year-over-year, alongside a revenue decrease from $0.4 …
Nov 12, 2026 Corporate Catalyst Neutral Impact 55
Absci Appoints Gerry Muhle as Chief Commercial Officer
Absci Corporation has appointed Gerry Muhle as its Chief Commercial Officer. This is a significant internal corporate development as a new CCO is typically brought in to drive reve…
Nov 12, 2026 Corporate Catalyst Neutral Impact 65
Gerry Muhle Departs Galderma to Join Absci as Chief Commercial Officer
Gerry Muhle has left his role as Senior Vice President and Head of Global Product Strategy at Galderma to become the Chief Commercial Officer at Absci. This appointment is a positi…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Jefferies Initiates Coverage of Absci Corporation with Buy Rating
Jefferies, a prominent investment bank, has initiated coverage on Absci Corporation (ABSI) with a 'Buy' rating and a $14 price target. This event is significant because new analyst…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Jefferies Initiates Coverage of Absci Corporation with Buy Rating
Jefferies, a prominent investment bank, has initiated coverage on Absci Corporation, a company specializing in AI-designed antibody therapeutics. This action includes a 'Buy' ratin…
Oct 16, 2026 Corporate Catalyst Bullish Impact 65
Keybanc Maintains Overweight on Absci, Raises Price Target to $20
Keybanc analyst Scott Schoenhaus maintained an 'Overweight' rating on Absci and raised the price target from $16 to $20. This action signals increased confidence from the analyst i…
Oct 12, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
The filing reports that HC Wainwright & Co. has reiterated its 'Buy' rating and $16 price target for Absci. This action by a research firm signals continued confidence in Absci's p…
Sep 8, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Absci, Raises Price Target to $16
BTIG analyst Kambiz Yazdi has maintained a 'Buy' rating on Absci and raised the price target from $13 to $16. This action signals increased confidence from the analyst in Absci's f…
Aug 12, 2026 Corporate Catalyst Bearish Impact 85
Absci shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline represents a direct corporate catalyst, as the company's specific financial performance is driving the stock movement. The impact score is high because earnings repor…
Aug 11, 2026 Corporate Catalyst Bearish Impact 85
Absci shares are trading lower after the company reported worse-than-expected Q2 financial results.
The worse-than-expected Q2 financial results for Absci (ABSI) are a direct corporate catalyst, leading to a significant negative impact on its share price. This indicates that the …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.